Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOXR1030 in GPC3-positive solid tumors
ISRCTN15110275Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Oct 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of GPC3-CART cells in hepatocellular carcinoma (HCC), Pulmonary squamous cell carcinoma, Merkel cell carcinoma (MCC) and 1 more, sponsored by SOTIO Biotech. Primary endpoints: Dose-limiting toxicities, Maximum tolerated dose and 2 more. Started Oct 2022; status: completed.
02
Drugs
GPC3-CART cells
03
Conditions
hepatocellular carcinoma (HCC)Pulmonary squamous cell carcinomaMerkel cell carcinoma (MCC)Myxoid/round cell liposarcoma (MRCLS)
Beyond the preview
Go deeper on ISRCTN15110275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15110275.